Journal Article

Treatment of chronic hepatitis C: another therapeutic option

C. Trepo, F. Bailly and T. Bizollon

in Nephrology Dialysis Transplantation

Volume 11, issue supp4, pages 62-64
Published in print January 1996 | ISSN: 0931-0509
Published online January 1996 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/11.supp4.62
Treatment of chronic hepatitis C: another therapeutic option

Show Summary Details

Preview

Ribavirin is a nucleoside analogue with antiviral activity against a number of DNA and RNA viruses. That molecule is administered per os and its most frequent adverse effect is haemolysis, moderate in most cases. Used alone, ribavirin normalized liver enzyme concentrations in 45% of patients while viraemia is not significantly modified. Histological improvement is observed in responder patients. The most interesting results have been obtained by associating ribavirin with interferon. In patients who have never been treated, a six-month course of ribavirin-interferon association produced a lasting and total response in 47% of patients versus 25% in patients treated with interferon alone. In relapsers, this bi-therapy produced total and prolonged response in more than 40% of cases and in 20% of non-responder patients. Lastly, that association appears promising in treating hepatitis C reinfection after liver transplantation.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.